Global Insomnia Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Formulation;

Capsules, Tablet, and Others

By Treatment Type;

Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonist, Melatonin Antagonist, Devices, and Others

By Therapy Type;

Non Pharmacological Therapy and Pharmacological Therapy

By Diseases Condition;

Poor Quality Of Sleep, Sleep Maintenance, and Other

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn111875852 Published Date: May, 2025 Updated Date: June, 2025

Insomnia Market Overview

Insomnia Market (USD Million)

Insomnia Market was valued at USD 4,945.22 million in the year 2024. The size of this market is expected to increase to USD 6,291.70 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 3.5%.


Global Insomnia Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 3.5 %


Study Period2025 - 2031
Base Year2024
CAGR (%)3.5 %
Market Size (2024)USD 4,945.22 Million
Market Size (2031)USD 6,291.70 Million
Market ConcentrationHigh
Report Pages369
4,945.22
2024
6,291.70
2031

Major Players

  • Pfizer Inc
  • Takeda Pharmaceutical Company Ltd
  • Sanofi S.A
  • Idorsia Pharmaceuticals Ltd
  • Electromedical
  • Merck & Co
  • Aurobindo Pharma Limited
  • Astellas Pharma

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Insomnia Market

Fragmented - Highly competitive market without dominant players


The insulinoma market is experiencing strong growth, driven by rising awareness of insulinomas and continuous advancements in diagnostic and treatment methods. Insulinomas, which are rare pancreatic neuroendocrine tumors, require effective, timely intervention, fueling the demand for innovative healthcare solutions. Early detection plays a crucial role in managing insulinoma cases, with nearly 65% of diagnoses occurring in individuals between 30 and 60 years old. This trend is expected to contribute significantly to the market’s expansion.

Technological Advancements and Market Growth
Technological progress in diagnostic imaging and medical procedures is enhancing the detection and treatment of insulinomas. Cutting-edge technologies in imaging allow for more accurate diagnoses, leading to better treatment outcomes. Additionally, advancements in minimally invasive surgery, such as laparoscopic and robotic techniques, have transformed insulinoma management by offering patients reduced recovery times and fewer complications. The adoption of these innovations is expected to contribute to a robust market growth rate of 7%, reflecting the increasing need for effective insulinoma management.

Rising Demand for Advanced Treatment Solutions
As the demand for effective insulinoma treatments continues to grow, patients are seeking both surgical and non-surgical options that offer long-term management. Around 50% of insulinoma cases require surgery for complete tumor removal, but a growing preference for non-invasive treatments, such as medical therapies and targeted therapies, is emerging. This shift in patient preferences is expected to drive market innovation, with a focus on personalized care and improved survival rates.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Formulation
    2. Market Snapshot, By Treatment Type
    3. Market Snapshot, By Therapy Type
    4. Market Snapshot, By Diseases Condition
    5. Market Snapshot, By Region
  4. Insomnia Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising prevalence of sleep disorders
        2. Growing awareness of mental health
        3. Increased demand for OTC sleep aids
        4. Technological advances in sleep tracking
      2. Restraints
        1. Side effects of prescription drugs
        2. Lack of long-term treatment efficacy
        3. Social stigma around mental disorders
        4. Limited availability of behavioral therapies
      3. Opportunities
        1. Growing Demand for Natural Remedies
        2. Expansion in Emerging Markets
        3. Research and Development Investments
        4. Personalized Medicine Approaches
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Insomnia Market, By Drug Formulation, 2021 - 2031 (USD Million)
      1. Capsules
      2. Tablet
      3. Others
    2. Insomnia Market, By Treatment Type, 2021 - 2031 (USD Million)
      1. Benzodiazepines
      2. Nonbenzodiazepines
      3. Antidepressants
      4. Orexin Antagonist
      5. Melatonin Antagonist
      6. Devices
      7. Others
    3. Insomnia Market, By Thearpy Type, 2021 - 2031 (USD Million)
      1. Non Pharmacological Therapy
      2. Pharmacological Therapy.
    4. Insomnia Market, By Diseases Condition, 2021 - 2031 (USD Million)
      1. Poor Quality Of Sleep
      2. Sleep Maintenance
      3. Others
    5. Insomnia Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. CURRAX PHARMACEUTICALS LLC
      2. EISAI CO. LTD
      3. Vanda Pharmaceuticals Inc.
      4. Merck KGaA
      5. Zydus Cadila
      6. VIATRIS INC
      7. MINERVA NEUROSCIENCES INC
      8. Sanofi
      9. Takeda Pharmaceutical Company Ltd
      10. Pfizer Inc.
  7. Analyst Views
  8. Future Outlook of the Market